NEW YORK – Novartis is gearing up to meet a threefold growth in patient demand for Pluvicto (vipivotide tetraxetan), betting ...

Pfizer's oncology revenues jumped 30 percent in the third quarter, with growth from several precision oncology drugs.

In a Phase III trial, more patients on Scemblix had a major molecular response than on investigator-selected tyrosine kinase inhibitors.

The financing will allow the firm to further develop its AI platform, develop drugs in best responders, and acquire new pipeline candidates.

The FDA had asked for more chemistry, manufacturing, and controls information after reviewing an earlier BLA on the investigational therapy.

The partners are also studying their personalized vaccine with Keytruda as an adjuvant NSCLC treatment for those who haven't gotten neoadjuvant therapy.

The companies have plans to evaluate IDE275 as a monotherapy and combined with immunotherapy in MSI-high solid tumors.

Through the acquisition, AbbVie will gain Aliada's lead asset, a beta-amyloid-targeting drug in a Phase I trial designed to cross the blood-brain barrier.

The efficacy seen in a small study, especially in GNAS-mutated tumors, could influence care, but the rarity of the cancer is ...

When doctors and other types of providers provide pretest genetic testing education to patients, it allows Clearview's ...

Broad Institute and Northwestern University researchers are encouraging others to examine noncoding genes, when investigating ...

NEW YORK – Researchers have identified a gene signature that can predict whether early-stage breast cancer patients will ...